A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer

Published:2013-12 Issue:4 Volume:11 Page:397-406
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Armstrong Andrew J.,Shen Tong,Halabi Susan,Kemeny Gabor,Bitting Rhonda L.,Kartcheske Patricia,Embree Elizabeth,Morris Karla,Winters Carolyn,Jaffe Tracy,Fleming Mark,George Daniel J.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference44 articles.

1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial;de Bono;Lancet,2010

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study;Fizazi;Lancet,2011

4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

5. Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer;Antonarakis;Prostate Cancer Prostatic Dis,2011

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring potential therapeutic combinations for castration-sensitive prostate cancer using supercomputers: a proof of concept study;Scientific Reports;2024-08-13

2. In silico exploration of anti-prostate cancer compounds from differential expressed genes;BMC Urology;2024-07-03

3. The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy;Prostate Cancer and Prostatic Diseases;2024-01-31

4. Recent advances and future perspectives in the therapeutics of prostate cancer;Experimental Hematology & Oncology;2023-09-22

5. Current use of Molecular Mechanisms and Signaling Pathways in Targeted Therapy of Prostate Cancer;Current Pharmaceutical Design;2023-09